daytrading dec 30 pre-market, page-105

  1. oppietrader
    5,377 Posts.
    lightbulb Created with Sketch. 2
    clock Created with Sketch.
    30/12/13
    11:12
    Post #: 12749560
    RGS: has a mention on The Australian Top 100 picks for 2014
    by: Tim Blue From: The Australian December 28, 2013 12:00AM

    I copied this from RGS thread. thanks to Oilyman


    61 Regeneus (RGS)

    A REGENERATIVE medicine company that is commercialising cell-based therapies for treating conditions such as arthritis in humans and animals. BBY suggests it is well placed to benefit from legislation passed by Japan's Upper House in early December that allows fast-track approval of stem cell therapies. The new legislation opens the way for RGS to launch an off-the-shelf human stem-cell therapy for osteoarthritis in Japan within three to four years, if it can demonstrate safety and efficacy in clinical trials. BBY has it as a spec buy with a target price of 76c a share.
    Likes Created with Sketch. 1  Upvote
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

TX3 Canadian fieldwork yields multiple pegmatites for Trinex
right-arrow Created with Sketch.
IMM Immutep reports strong response rate from immunotherapies treating carcinomas
right-arrow Created with Sketch.
TLX Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
right-arrow Created with Sketch.
AUG Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree
right-arrow Created with Sketch.
RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
right-arrow Created with Sketch.
NEWS What matters for FY25: Investment; interest rates; inflation & elections
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.